The aim of the study was to investigate the influence of long-term biologic therapy with TNF-α inhibitors (adalimumab, etanercept, infliximab) on the levels of adipokines (resistin, adiponectin, leptin) in relation to PASI (Psoriasis Activity and Severity Index), DLQI (Dermatology Life Quality Index), BMI (Body Mass Index) and lipid profile (TG—triglyceride , TC—total cholesterol, LDL—low density lipoprotein, HDL—high density lipoprotein) change. Here, RETN is linked to psoriasis.